Abbott Laboratories (New York Stock Exchange:ABT)
| Market Cap | 182.12B-20.2% |
| Revenue (ttm) | 46.59B+8.1% |
| Net Income | 5.42B-61.2% |
| EPS | 3.11-61.0% |
| Shares Out | 1.73B |
| PE Ratio | 33.84 |
| Forward PE | 17.35 |
| Dividend | $2.48(2.36%) |
| Ex-Dividend Date | Jul 15, 2026 |
| Volume | 6,386,483 |
| Open | 105.69 |
| Previous Close | 105.52 |
| Day's Range | 104.79 - 106.85 |
| 52-Week Range | 81.97 - 137.49 |
| Beta | 0.59 |
| Analysts | Buy |
| Price Target | 123.64(+17.47%) |
| Earnings Date | Oct 21, 2026 |
About ABT
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$ABT stock is featured in our Insider Score Rankings, Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of ABT by members of U.S. Congress
| Politician | Type | Traded |
|---|---|---|
| Rich McCormickHouse / R | Sale$1.00K – $15.00K | Jul 30, 2026 |
| Mike KellyHouse / R | Sale$1.00K – $15.00K | Jul 17, 2026 |
| Mike KellyHouse / R | Sale$1.00K – $15.00K | Jul 16, 2026 |
| Rick W. AllenHouse / R | Sale$15.00K – $50.00K | Jul 14, 2026 |
| Richard W. AllenHouse / R | Sale$15.00K – $50.00K | Jul 14, 2026 |
| Rick W. AllenHouse / R | Sale$15.00K – $50.00K | Jul 13, 2026 |
| Rich McCormickHouse / R | Purchase$1.00K – $15.00K | Jun 12, 2026 |
| Rick W. AllenHouse / R | Sale$15.00K – $50.00K | Apr 15, 2026 |
Recently reported changes in ABT holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by ABT's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
ABT Estimated quarterly lobbying spending
Source: U.S. Senate LDA
ABT Revenue by Segment or Geography
Source: SEC EDGAR (10-Q/10-K)
U.S. Patents
New ABT patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to ABT from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in ABT
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $5.86B |
| SCHDSchwab U.S. Dividend Equity ETF | $5.08B |
| VOOVanguard S&P 500 ETF | $4.83B |
| IVViShares Core S&P 500 ETF | $2.48B |
| SPYState Street SPDR S&P 500 ETF | $2.26B |
| VTVVanguard Morningstar Value ETF | $1.75B |
Estimated from each fund’s disclosed top holdings × AUM
ABT Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from ABT’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score